Trimetazidine-Biocom mV Table n / rev modif.vysv. 35mg 60 pc

$6.70

Trimetazidine-Biocom mV Table n / rev modif.vysv. 35mg 60 pc

5 in stock

Quantity:

Description

Composition
Active substance:
Trimetazidine dihydrochloride 35 mg.
Excipients:
Calcium hydrogenphosphate dihydrate, hypromellose (hydroxypropylmethylcellulose 4000), povidone (polyvinylpyrrolidone, low molecular weight Medical), colloidal silica (Aerosil), magnesium stearate.
shell composition: hypromellose (hydroxypropylmethylcellulose 4000), Macrogol (polyethylene glycol 6000), titanium dioxide, iron oxide red.
Description:
Tablets coated pink, round, biconvex.
Product form:
The modified-release tablets, coated tablets, 35 mg.
10 tablets in blisters made of PVC film and aluminum foil.
6 the contour of cellular packages together with instructions for use in a cardboard package.
Contraindications
– Hypersensitivity to any component of the drug;
– Renal impairment (creatinine clearance less than 15 mL / min);
– Severe hepatic dysfunction;
– Pregnancy;
– The period of breast-feeding;
– Age 18 years (effectiveness and safety have been established).
Dosage
35 mg
Indications
– Ischemic heart disease: prevention of angina attacks (in the complex therapy);
– chorioretinal vascular disorders;
– Vertigo of vascular origin;
– cochle-vestibular disorders ischemic nature (tinnitus, hearing impairment).
Interaction with other drugs
No information.
Overdose
Currently, the cases of overdose have been reported.
pharmachologic effect
Pharmacological group:
Antihypoxanth means.
Pharmacodynamics:
Trimetazidine has antianginal, antihypoxia action. Directly affecting the cardiomyocytes and neurons in the brain, it improves their metabolism and function. Cytoprotective effect is due to an increase in potential energy, the activation of the oxidative decarboxylation and the rationalization of oxygen consumption (increasing aerobic glycolysis and fatty acid oxidation blockade). Supports myocardial contractility, prevents a decrease in intracellular ATP and phosphocreatine. In acidosis conditions normalize the functioning of ionic channels and prevents the accumulation of calcium and sodium in cardiomyocytes normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and phosphate concentration caused by myocardial ischemia and reperfusion. Prevents the damaging action of free radicals, preserves the integrity of cellular membranes, prevents activation of neutrophils in the ischemic area, increases the electric potential decreases the yield of creatine from the cells and the severity of ischemic myocardial injury.
When the frequency of attacks of angina reduces (decreases nitrate consumption) after 2 weeks of treatment increases exercise capacity, reduced blood pressure drops. Improved hearing and vestibular results of samples from patients, decreases dizziness and tinnitus.
When vascular eye disease restores the functional activity of the retina eyes.
Pharmacokinetics:
After taking the drug inside Trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%. Time to maximum plasma concentration – 2 hours. The maximum concentration after a single dose of 35 mg of trimetazidine about 55 ng / ml. Easily penetrates the blood-tissue barriers. The half-life (T1 / 2) is 4.5-5 hours. Communication with plasma proteins – 16%. It is derived from the body by the kidneys (approximately 60% unchanged).
Conditions of supply of pharmacies
By prescription.
side effects
Allergic reactions (pruritus). Rarely from the gastrointestinal tract: gastralgia, nausea, vomiting; headache, feeling of palpitations.
special instructions
The drug is not intended for the relief of angina attacks!
On the background of treatment in patients with coronary heart disease is a significant decrease in daily requirement of nitrates.
Use of the drug has no effect on the ability to control the car and the performance of work requiring a high rate of mental and physical reactions.
Storage conditions
In a dry place, protected from light at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside, during a meal time.
The recommended dosing regime – 2 tablets (70 mg) per day in 2 divided doses. The course of treatment recommended by the doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

BIOCOM

There are no reviews yet.

Add your review